NCT07116824View on ClinicalTrials.gov

HB1801 Combined Treatment of HER2-positive Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

July 15, 2026

Study Completion Date

November 7, 2027

Conditions
HER2-positive Breast Cancer
Interventions
DRUG

HB1801

HB1801 is administered by intravenous infusion.

DRUG

Trastuzumab

Trastuzumab is administered by intravenous infusion, 8mg/kg loading dose and then 6mg/kg per cycle, Q3W.

DRUG

Pertuzumab

Pertuzumab is administered by intravenous infusion, 840mg loading dose and then 420mg per cycle, Q3W.

DRUG

Docetaxel

Docetaxel is administered by intravenous infusion, 75mg/m\^2, Q3W.

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY